correction
vaccinex
present
additional
signal
data
huntington
study
group
medical
conference
signal
phase
trial
data
continue
support
cognitive
benefit
reduced
brain
atrophy
pepinemab
treatment
huntington
disease
data
provide
strong
rationale
continued
development
huntington
slowly
progressive
neurodegenerative
diseases
including
alzheimer
rochester
globe
newswire
release
issued
headline
earlier
today
vaccinex
nasdaq
vcnx
please
note
original
version
press
release
third
paragraph
indicated
interested
participants
would
able
register
hsg
charge
however
nominal
fee
interested
participants
may
register
event
corrected
release
follows
vaccinex
nasdaq
vcnx
biotechnology
company
pioneering
differentiated
approach
treating
cancer
neurodegenerative
disease
inhibition
today
announced
report
additional
data
recently
completed
phase
signal
study
pepinemab
huntington
disease
hd
virtual
huntington
study
group
hd
focus
medical
conference
take
place
october
new
data
suggest
pepinemab
potential
provide
cognitive
benefit
slow
brain
atrophy
hd
patients
maurice
zauderer
chief
executive
officer
vaccinex
present
learnings
signal
phase
study
treatment
pepinemab
antibody
et
friday
october
original
version
press
release
indicated
interested
participants
would
able
register
hsg
charge
nominal
fee
interested
participants
may
register
event
analysis
data
signal
study
continues
provide
insights
pepinemab
treatment
effects
key
observations
analyses
reported
conference
include
highly
significant
treatment
benefit
pepinemab
reflected
assessment
battery
composite
index
signal
benefit
provided
analysis
treating
physicians
clinical
global
impression
change
subpopulation
patients
advanced
disease
progression
exploratory
volumetric
mri
analysis
brain
patients
early
manifest
disease
demonstrate
treatment
related
reduction
brain
atrophy
company
believes
results
provide
strong
rationale
continued
development
pepinemab
treatment
option
hd
well
slowly
progressive
neurodegenerative
diseases
phase
study
main
goal
signal
identify
patient
population
benefit
selected
treatment
characterize
endpoints
employed
evaluate
treatment
benefit
population
safety
data
study
also
indicate
pepinemab
suggest
opportunity
combination
treatment
agents
based
independent
mechanism
action
currently
development
treatment
discontinuation
study
rates
remarkably
low
extended
study
time
period
appear
increase
serious
adverse
events
relative
placebo
vaccinex
vaccinex
pioneering
differentiated
approach
treating
neurodegenerative
disease
inhibition
semaphorin
key
driver
neuroinflammation
company
lead
drug
candidate
pepinemab
blocks
potential
treatment
huntington
alzheimer
neurodegenerative
diseases
beyond
neurology
vaccinex
believes
combination
checkpoint
inhibitors
pepinemab
potential
increase
objective
responses
oncology
company
additionally
intends
leverage
proprietary
drug
discovery
platform
create
opportunities
future
pipeline
expansion
strategic
collaborations
particularly
relation
selection
high
value
antibodies
important
membrane
receptors
forward
looking
statements
extent
statements
contained
press
release
descriptions
historical
facts
regarding
vaccinex
vaccinex
us
statements
reflecting
management
current
beliefs
expectations
words
may
expect
anticipate
estimate
intend
potential
advance
similar
expressions
negatives
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
examples
statements
press
release
include
among
others
statements
expected
timing
results
ongoing
future
clinical
trials
expectations
regarding
potential
benefits
activity
effectiveness
product
candidates
statements
may
involve
substantial
risks
uncertainties
could
cause
research
development
programs
clinical
development
programs
future
results
performance
achievements
differ
significantly
expressed
implied
statements
risks
uncertainties
include
among
others
uncertainties
inherent
execution
cost
completion
preclinical
clinical
trials
uncertainties
related
regulatory
approval
history
operating
losses
need
raise
additional
capital
continue
going
concern
risks
related
indebtedness
risks
related
dependence
lead
product
candidate
pepinemab
impact
pandemic
matters
could
affect
development
plans
commercial
potential
product
candidates
except
required
law
assume
obligation
update
statements
discussion
factors
could
cause
future
results
differ
materially
statement
see
section
titled
risk
factors
periodic
reports
filed
securities
exchange
commission
sec
risks
uncertainties
described
form
filed
sec
march
subsequent
periodic
reports
investor
contact
media
contact
jeremy
feffer
cait
williamson
lifesci
advisors
llc
lifesci
communications
llc
jeremy
cait
